相关实验视频

Updated: Jun 17, 2025

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner

Published on: June 7, 2024

在阿尔茨海默氏症患者中,大脑葡萄糖代谢

Eric Salmon¹, Fabienne Collette¹, Christine Bastin¹

¹GIGA Research, CRC Human Imaging, University of Liege, Liege, Belgium.

Cortex; a journal devoted to the study of the nervous system and behavior

|August 14, 2024

概括

18F--脱氧-葡萄糖正子发射断层扫描 (FDG-PET) 是诊断阿尔茨海默病 (AD) 的一个有价值的工具. 本综述强调了FDG-PET在识别大脑代谢变化,帮助诊断和理解疾病异质性的作用.

科学领域:

神经成像是一种神经成像.
神经学神经学
核医学就是核医学.

背景情况:

18F--脱氧-葡萄糖正子发射断层扫描 (FDG-PET) 是诊断阿尔茨海默氏病 (AD) 的关键准临床检查.
在临床可能的AD中进行的精子研究已经确定了后脑代谢下降和海马体代谢变化的重要性.
FDG-PET模式在病理确认的AD病例中表现出敏感性,并在区分痴呆症条件中发挥作用.

研究的目的:

审查关于FDG-PET在阿尔茨海默病诊断和进展中的开创性研究.
探索FDG-PET在差异诊断和理解AD异质性的作用.
检查FDG-PET发现,认知功能和其他生物标志物之间的相关性.

主要方法:

在临床可能的AD中进行的开端研究的叙述性综述.
与病理确认和差异诊断有关的FDG-PET模式的分析.
在FDG-PET解释中研究自动化数据分析技术和机器学习.

主要成果:

FDG-PET模式是阿尔茨海默病的敏感指标,有助于差异诊断,并预测预发性阿尔茨海默病的转化.
自动化分析和机器学习方法显示FDG-PET数据的可变可靠性.
FDG-PET揭示了AD的临床异质性,识别了低代谢亚型,并与情节性记忆等认知功能相关联.

结论:

FDG-PET是阿尔茨海默病的敏感诊断和预后工具,反映了疾病的异质性.
通过FDG-PET识别的代谢模式与特定的认知缺陷相关,并且可以在临床前阶段观察到.
在没有经典的AD蛋白病症的情况下,FDG-PET发现提供了对替代病理机制和差异诊断的见解.

关键词:

大脑新陈代谢大脑新陈代谢痴呆症是一种痴呆症.德国联邦财政部-PET 记忆记忆记忆记忆记忆轻度认知障碍轻度认知障碍

更多相关视频

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

A Dual Tracer PET-MRI Protocol for the Quantitative Measure of Regional Brain Energy Substrates Uptake in the Rat

Published on: December 28, 2013

相关概念视频

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...